4) 20 (28.6) 47 (49.0) 0.0076 Reduced 99 (59.6) 50 (71.4) 49 (51.0) Relationship Luminespib cost between Twist Selleckchem Acadesine expression and clinicopathological findings according to E-cadherin expression The tumors were divided into the preserved E-cadherin group and reduced E-cadherin group. In the E-cadherin preserved group, the expression of Twist was related to lymphatic
invasion; in the E-cadherin reduced group, the expression of Twist was related to depth of tumor invasion and stage (Table 2). Table 2 Relationship between Twist expression and clinicopathological findings according to E-cadherin expression E-cadherin preserved P E-cadherin reduced P Characteristics Twist high Twist low Twist high Twist low n = 20 (29.9%) n = 47 (70.2%) n =50 (50.5%) n = 49 (49.5%) Histology Well 7 (35.0) 17 (36.2) 0.74 24 (48.0) 15 (30.6) 0.20 Moderate 10 (50.0) 26 (55.3) 17 (34.0) 23 (46.9) Poor 3 (15.0) 4 (8.5) 9 (18.0) 11 https://www.selleckchem.com/products/SNS-032.html (22.5) pT pT1 8 (40.0) 25 (53.2) 0.28 2 (4.0) 11 (22.5) 0.027 pT2 4 (20.0) 7 (14.9) 6 (12.0) 8 (16.3) pT3 3 (15.0) 11 (23.4) 31 (62.0) 22 (44.9) pT4 5 (25.0) 4 (8.5) 11 (22.0) 8 (16.3) pN pN0 10 (50.0) 34 (72.3) 0.082 11 (22.0) 10 (20.4) 0.85 pN1 10 (50.0)
13 (27.7) 39 (78.0) 39 (79.6) pM pM0 16 (80.0) 42 (89.4) 0.32 26 (52.0) 34 (69.4) 0.076 pM1 4 (20.0) 5 (10.6) 24 (48.0) 15 (30.6) pStage I 7 (35.0) 19 (40.4) 0.24 0 (0.0) 4 (8.2) 0.0022 IIA 2 (10.0) 13 (27.7) 8 (16.0) 6 (12.2) IIB 3 (15.0) 7 (14.9) 1 (2.0) 10 (20.4) III 4 (20.0) 3 (6.4) 17 (34.0) 14 (28.6) IV 4 (20.0) 5 (10.6) 24 (48.0) 15 (30.6) Lymphatic invasion Positive 14 (70.0) 19 (40.4) 0.025 41 (82.0) 33 (67.4) 0.092 Negative 6 (30.0) 28 (59.6) 9 (18.0) 16 (32.7) Venous invasion Positeive 8 (40.0) 9 (19.2) 0.080 18 (36.0) 16 (32.7) 0.73 Negative 12 (60.0) 38 (80.9) 32 (64.0)
33 (67.4) Relationship between prognosis and expression of Twist and E-cadherin Seven of the patients died of postoperative complications Roflumilast within 30 days of the beginning of the study period, leaving 159 patients for survival analysis. The 5-year survival rate of patients with tumors with low and high Twist expression was 41.6%, whereas the rate for high Twist expression was 23.0%.There was a significant difference in 5-year survival rate between low and high expression of Twist (P = 0.0014; Fig. 2A). The 5-year survival rate of patients with tumors with preserved and reduced E-cadherin expression was 48.7% and 23.3%, respectively, and the difference was significant (P = 0.0007; Fig.